Robert T. Nelsen — Co-Founder and Director at Juno Therapeutics

Mr. Robert T. Nelsen, also known as Bob, is a Co-Founder, Partner and Managing Director of ARCH Venture Partners, L.P., ARCH Venture Fund V, L.P., Arch Venture Fund VIII, L.P. and ARCH Venture Fund VI, L.P. Mr. Nelsen joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than thirty companies, including 15 which have reached valuations exceeding $1 billion. He focuses on alternative energy, biotechnology, pharmaceuticals, disruptive innovation and nanotechnology. He is associated with ARCH Venture since July 1994. He is a Co-Founder of Juno Therapeutics, Inc. He co-founded Vir Biotechnology, Inc. in 2016. From April 1987 to July 1994, he served as a Senior Manager of ARCH Development Partners, L.L.C., where he was responsible for new company formation. He serves as the Chairman of Hua Medicine (Shanghai) Ltd. He served as the Chairman of Netbot, Inc. He has been a Director at Sienna Biopharmaceuticals, Inc. since October 2015. He has been an Independent Director of NeurogesX, Inc. since July 2000. He has been a Director of Unity Biotechnology, Inc. since 2011; Ikaria, Inc. since March 2007; Syros Pharmaceuticals, Inc. since November 2011; and Juno Therapeutics, Inc. since August 2013. He serves as a Director of Kilimanjaro Energy, Inc.; GoCampus, Inc.; Nura Inc.; Sapphire Energy, Inc.; GreaterGood.com, Inc.; deCODE Genetics; Ensemble Discovery Corp.; Ares Bioscience GmbH; Ensemble Therapeutics Corporation; Cenexys, Inc.; Denali Therapeutics Inc.; Bluebird Bio; XenoPort, Trubion Pharmaceuticals; GenVec; IDUN Pharmaceuticals; Theraclone Sciences; NextCODE Health; Semma Therapeutics; Faraday Pharmaceuticals; Vir Biotechnology, Inc; and GRAIL, Inc. He serves as Director Emeritus of Institute for Systems Biology. He serves as a Trustee/Director of Fred Hutchinson Cancer Research Center. He served as a Director of Institute for Systems Biology. He served as a Director of Agios Pharmaceuticals, Inc. since December 2007. He served as a Director of Bellerophon Therapeutics, Inc. from February 2014 to December 1, 2015. He served as a Director of Fate Therapeutics, Inc. from September 2007 to June 6, 2014 and Kythera BioPharmaceuticals, Inc. from January 2006 to January 5, 2015. He served as a Director of Xcyte Therapies Inc. since August 1996. He served as a Director of Genomica Corp. since 1997. He served as a Director of Caliper Technologies Corp. from September 1995 to February 2004. He served as a Director of Illumina, Inc. since June 1998. He served as a Director of Sage Therapeutics, Inc. from September 2013 to March 15, 2016. He served as a Director of Accelerator Corporation and Surface Logix, Inc. He served a Director of Theraclone, NetBot, Inc., Alnylam Pharmaceuticals, Inc., Everyday Learning Corporation, Spaltudaq, Array BioPharma, R2 Technology, ImproveNet, Inc. and Classmates.com. He served as a Director of Caliper Life Sciences, Inc. from September 1995 to February 2004. He served as a Director of Adolor Corporation from 1994 to May 21, 2008. He served as Director of Elixir Pharmaceuticals, Inc., until September 2007. He served as a Director of the National Venture Capital Association, Arivale and Aledade. He served as a Director of Emergent Product Development Seattle LLC until January 2006. He served as a Director of Converge Medical, Inc., Integrated Diagnostics Inc., Prizm Pharmaceuticals, Receptos, Inc., Celebrate Express Inc. and Optobionics Corporation. He served as Board Observer of Chiasma (Israel) ltd. and VLST Corporation. He received an M.B.A. from the University of Chicago and a B.S. in Biology and Economics from the University of Puget Sound.